Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects

Virology Journal

Volumn 7, Issue , 2010, Pages

  Branco, Luis M ^a,b   Grove, Jessica N ^a   Moses, Lina M ^c   Goba, Augustine ^c,e   Fullah, Mohammed ^e   Momoh, Mambu ^e   Schoepp, Randal J ^d   Bausch, Daniel G ^c   Garry, Robert F ^f  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Autoimmune Technologies LLC   (United States)

^c TULANE UNIVERSITY   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^e Kenema Government Hospital   (Sierra Leone)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN 1;

ARTICLE; ENERGY EXPENDITURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LASSA FEVER; SIERRA LEONE; TISSUE INJURY; VIRION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS SHEDDING; WESTERN BLOTTING;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LASSA FEVER; LASSA VIRUS; MODELS, BIOLOGICAL; VIRAL ENVELOPE PROTEINS;

EBOLA VIRUS; LASSA VIRUS; MARBURGVIRUS;

EID: 78049525115     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-306     Document Type: Article

References (29)

1. Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding. MM Illick LM Branco JN Fair KA Illick A Matschiner R Schoepp RF Garry MC Guttieri, Virology J 2008 5 161 10.1186/1743-422X-5-161
2. Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. LM Branco RF Garry, Virology J 2009 6 147 10.1186/1743-422X-6-147
3. Ectodomain shedding of the glycoprotein GP of Ebola virus. O Dolnik V Volchkova W Garten C Carbonnelle S Becker J Kahnt U Ströher HD Klenk V Volchkov, The EMBO J 2004 23 2175 2184 10.1038/sj.emboj.7600219 (Pubitemid 38737744)
4. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. V Wahl-Jensen SK Kurz PR Hazelton HJ Schnittler U Ströher DR Burton H Feldmann, J Virol 2005 79 4 2413 2419 10.1128/JVI.79.4.2413-2419.2005 15681442
5. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. VM Wahl-Jensen TA Afanasieva J Seebach U Ströher H Feldmann HJ Schnittler, J Virol 2005 79 16 10442 10450 10.1128/JVI.79.16.10442- 10450.2005 16051836
6. Lassa fever vaccine: A review. SP Fisher-Hoch JB McCormick, Expert Rev Vaccines 2004 3 103 111 10.1586/14760584.3.2.189 (Pubitemid 38470528)
7. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. JB McCormick, Med Microbiol Immunol 1986 175 153 155 10.1007/BF02122438 3724661
8. Epidemiology and control of Lassa fever. JB McCormick, Current Topics in Microbiol and Immunol 1987 134 69 78
9. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. SP Fisher-Hoch O Tomori A Nasidi GI Perez-Oronoz Y Fakile L Hutwagner JB McCormick, Br Med J 1995 311 857 859
10. A prospective study of the epidemiology and ecology of Lassa fever. JB McCormick PA Webb JW Krebs KMES Johnson ES Smith, J Infect Dis 1987 155 437 444 3805771
11. Lassa fever. Effective therapy with ribavirin. JB McCormick IJ King PA Webb CL Scribner RB Craven KM Johnson LH Elliot R Belmont-Williams, N Engl J Med 1986 314 20 26 10.1056/NEJM198601023140104 3940312
12. Arenaviridae: The viruses and their replication. MJ Buchmeier MD Bowen CJ Peters, Fields Virology Philadelphia: Lippincott-Raven, Knipe DM, Howley PM, 4 2001 1635 1668
13. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. O Lenz J ter Meulen HD Klenk NG Seidah W Garten, Proc Natl Acad Sci USA 2001 A98 12701 12705 10.1073/pnas.221447598 (Pubitemid 33020009)
14. The viral transmembrane superfamily: Possible divergence of arenavirus and filovirus glycoproteins from a common RNA virus ancestor. WR Gallaher C DiSimone MJ Buchmeier, BMC Microbiol 2001 1 1 10.1186/1471-2180-1-1 11208257
15. Structural and cell-associated proteins of Lassa virus. JC Clegg G Lloyd, J Gen Virol 1983 64 1127 1136 10.1099/0022-1317-64-5-1127 6405010
16. Localization of an arenavirus protein in the nuclei of infected cells. PR Young AC Chanas SR Lee EA Gould CR Howard, J Gen Virol 1987 68 2465 2470 10.1099/0022-1317-68-9-2465 3309183
17. Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies. FT Hufert W Ludke H Schmitz, Arch Virol 1989 106 201 212 10.1007/BF01313953 2476109
18. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. M Perez RC Craven JC de la Torre, Proc Natl Acad Sci USA 2003 100 22 12978 12983 10.1073/pnas.2133782100 14563923
19. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles. T Strecker R Eichler J Meulen W Weissenhorn H Dieter Klenk W Garten O Lenz, J Virol 2003 77 19 10700 10705 10.1128/JVI.77.19.10700- 10705.2003 12970458
20. Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). R Eichler T Strecker L Kolesnikova J ter Meulen W Weissenhorn S Becker HD Klenk W Garten O Lenz, Virus Res 2004 100 2 249 255 10.1016/j.virusres.2003.11. 017 15019244
21. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. T Strecker A Maisa S Daffis R Eichler O Lenz W Garten, Virol J 2006 3 93 10.1186/1743-422X-3-93 17083745
22. Viral protein determinants of Lassa virus entry and release from polarized epithelial cells. K Schlie A Maisa F Freiberg A Groseth T Strecker W Garten, J Virol 2010 84 7 3178 3188 10.1128/JVI.02240-09 20071570
23. Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. SL Ruo SW Mitchell MP Killey LF Roumillat SP Fisher-Hoch JB McCormick, J Gen Virol 1991 72 549 555 10.1099/0022-1317-72-3-549 1706408
24. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. DG Bausch PE Rollin AH Demby M Coulibaly J Kanu AS Conteh KD Wagoner LK McMullan MD Bowen CJ Peters T Ksiazek, J Clin Microbiol 2000 38 2670 2677 10878062
25. A clinical guide to viral haemorrhagic fever: Ebola, Marburg, and Lassa. Trop Doct. B Jeffs, 2006 36 1 1 14 16483416
26. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. LM Branco JN Grove FJ Geske ML Boisen IJ Muncy SA Magliato LA Henderson RJ Schoepp KA Cashman LE Hensley RF Garry, Virology J 2010 7 279 10.1186/1743-422X-7-279
27. The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen decoy and through Effects on Fc Receptor-Bearing Leukocytes. A Bukreyev L Yang J Fricke L Cheng JM Ward BR Murphy PL Collins, J Virol 2008 82 24 12191 12204 10.1128/JVI.01604-08 18842713
28. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. O Lenz J ter Meulen HD Klenk NG Seidah W Garten, Proc Natl Acad Sci USA 2001 98 22 12701 12705 10.1073/pnas.221447598 11606739
29. Cellular factors required for Lassa virus budding. S Urata T Noda Y Kawaoka H Yokosawa J Yasuda, J Virol 2006 8 4191 4195 10.1128/JVI.80.8.4191- 4195.2006 16571837